Johnson & Johnson said the company’s new nasal spray depression treatment Spravato will be priced at $590 for a 56-milligram dose and $885 for an 84-milligram dosage.

Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.

Alkermes Plc was told to conduct more clinical trials of the company’s experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval.

Heavy drinkers may be more likely than other adults to develop dementia, especially in middle age, a French study suggests.

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.

Researchers have discovered a protein that could help diagnose a degenerative brain disease commonly found in athletes, veterans of military service and others who have experienced brain trauma.

Pfizer Inc. announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.

Even during a humanitarian crisis, treating mental illnesses is not an optional luxury, experts said before a World Bank/World Health Organization meeting on the issue in Washington.

(Reuters Health) – People who drink coffee daily, even up to four cups per day, are less likely to die from heart disease, neurological disease, type 2 diabetes or suicide […]

At least one in five adult New Yorkers suffer from depression, substance abuse, suicidal thoughts or other psychological disorders every year, according to a report released on Thursday ahead of […]